

# Medication Safety in High-risk Situations



# **Medication Safety in High-risk Situations**

**Technical Report**

WHO/UHC/SDS/2019.10

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

**Suggested citation.** Medication Safety in High-risk Situations. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.10). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Designed by CommonSense, Greece

Printed by the WHO Document Production Services, Geneva, Switzerland

# Contents

Abbreviations .....	4
Preface .....	5
Executive summary: medication safety in high-risk situations .....	10
1. Introduction.....	11
2. Medication factors .....	12
2.1 Medications frequently considered as high-risk (high-alert).....	13
2.2 Other medications occasionally considered as high-risk (high-alert) .....	17
2.3 Strategies to reduce harm from high-risk (high-alert) medications.....	18
2.4 Potential actions to reduce medication-related harm due to medication factors in high-risk situations .....	20
3. Provider and patient factors .....	24
3.1 Health care professionals.....	24
3.2 Patients .....	26
3.3 Strategies to reduce medication errors related to provider and patient factors .....	27
4. Systems factors (work environment).....	29
4.1 Systems factors influencing medication safety .....	29
4.2 Strategies to reduce medication errors related to systems factors .....	29
5. Implications for countries .....	31
References .....	32
Annexes	
Annex 1. Glossary .....	40
Glossary references .....	43
Annex 2. Additional resources .....	45
Annex 3. List of contributors.....	46

# Abbreviations

ACE	angiotensin-converting enzyme
ADR	adverse drug reaction
aPTT	activated partial thromboplastin time
DOAC	direct-acting oral anticoagulant
INR	international normalized ratio
LASA	look-alike, sound-alike
LMWH	low molecular weight heparin
NOAC	newer oral anticoagulant
NSAID	non-steroidal anti-inflammatory drug
STOPP	screening tool for older people's prescriptions
UHC	universal health coverage
UFH	unfractionated heparin
WHO	World Health Organization

# Preface

Health care interventions are intended to benefit patients, but they can also cause harm. The complex combination of processes, technologies and human interactions that constitutes the modern health care delivery system can bring significant benefits. However, it also involves an inevitable risk of patient harm that can – and too often does – result in actual harm. A weak safety and quality culture, flawed processes of care and disinterested leadership teams weaken the ability of health care systems and organizations to ensure the provision of safe health care. Every year, a significant number of patients are harmed or die because of unsafe health care, resulting in a high public health burden worldwide.

Most of this harm is preventable. Adverse events are now estimated to be the 14th leading cause of morbidity and mortality in the world, putting patient harm in the same league as tuberculosis and malaria (1). The most important challenge in the field of patient safety (see Annex 1) is how to prevent harm, particularly avoidable harm, to patients during their care.

Patient safety is one of the most important components of health care delivery which is essential to achieve universal health coverage (UHC), and moving towards the UN Sustainable Development Goals (SDGs). Extending health care coverage must mean extending safe care, as unsafe care increase costs, reduces efficiency, and directly compromises health outcomes and patient perceptions. It is estimated that over half of all medicines are

prescribed, dispensed or sold inappropriately, with many of these leading to preventable harm (2). Given that medicines are the most common therapeutic intervention, ensuring safe medication use and having the processes in place to improve medication safety (see Annex 1) should be considered of central importance to countries working towards achieving UHC.

The Global Patient Safety Challenges of the World Health Organization (WHO) shine a light on a particular patient safety issue that poses a significant risk to health. Front-line interventions are then developed and, through partnership with Member States, are disseminated and implemented in countries. Each Challenge has so far focused on an area that represents a major and significant risk to patient health and safety (see Annex 1). In 2005, the Organization, working in partnership with the (then) World Alliance for Patient Safety, launched the first Global Patient Safety Challenge: *Clean Care Is Safer Care* (3), followed a few years later by the second Challenge: *Safe Surgery Saves Lives* (4). Both Challenges aimed to gain worldwide commitment and spark action to reduce health care-associated infection and the risks associated with surgery, respectively.

Recognizing the scale of avoidable harm linked with unsafe medication practices and medication errors, WHO launched its third Global Patient Safety Challenge: *Medication Without Harm* in March 2017, with the goal of reducing severe, avoidable medication-related harm by 50% over the next five years, globally (5).



This Challenge follows the same philosophy as the previous Challenges, namely that errors are not inevitable, but are very often provoked by weak health systems, and so the challenge is to reduce their frequency and impact by tackling some of the inherent weaknesses in the system.

As part of the Challenge, WHO has asked countries and key stakeholders to prioritize three areas for strong commitment, early action

and effective management to protect patients from harm while maximizing the benefit from medication, namely:

- medication safety in high-risk situations
- medication safety in polypharmacy
- medication safety in transitions of care.


Consider the following case scenario describing a medication error (see Annex 1) involving these three areas.

### Medication error: case scenario

Mrs Poly, a 65-year-old woman, came to the outpatient clinic complaining of abdominal pain and dark stools. She had a heart attack five years ago. At her previous visit three weeks ago she was complaining of muscle pain, which she developed while working on her farm. She was given a non-steroidal anti-inflammatory drug (NSAID), diclofenac. Her other medications included aspirin, and three medicines for her heart condition (simvastatin, a medicine to reduce her serum cholesterol; enalapril, an angiotensin-converting enzyme (ACE) inhibitor; and atenolol, a beta blocker). She was admitted to hospital as she developed symptoms of blood loss (such as fatigue and dark stools). She was provisionally diagnosed as having a bleeding peptic ulcer due to her NSAID, and her doctor discontinued diclofenac and prescribed omeprazole, a proton pump inhibitor. Following her discharge, her son collected her prescribed medicines from the pharmacy. Among the medicines, he noticed that omeprazole had been started and that all her previous medicines had been dispensed, including the NSAID. As his mother was slightly confused and could not remember exactly what the doctor had said, the son advised his mother that she should take all the medications that had been supplied. After a week, her abdominal pain continued and her son took her to the hospital. The clinic confirmed that the NSAID, which should have been discontinued (deprescribed), had been continued by mistake. This time Mrs Poly was given a medication list when she left the hospital which included all the medications she needed to take and was advised about which medications had been discontinued and why.

The events leading to the error in this scenario and how these could have been prevented are reflected in Figure 1, and the text below.

**Figure 1. Key steps for ensuring medication safety**



In this scenario the key steps that should have been followed to ensure medication safety in the inpatient setting include:

#### **1. Appropriate prescribing and risk assessment**

Medication safety should start with appropriate prescribing and a thorough risk-benefit

#### **2. Medication review**

A comprehensive medication review (see Annex 1) is a multidisciplinary activity whereby the risks and benefits of each medicine are considered with the patient and decisions made about future therapy. It optimizes the use of medicines for each individual patient.

Multiple medications especially involving two or more

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25203](https://www.yunbaogao.cn/report/index/report?reportId=5_25203)

